CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.
The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.
...Check out our new regulatory data on medical and recreational cannabis in 54 jurisdictions around the world
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries, using maps, and assesses the likelihood that the status quo may change in the future.
Available for purchase
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
